Merus (NASDAQ:MRUS) Expected to Announce Quarterly Sales of $12.39 Million

Equities analysts predict that Merus (NASDAQ:MRUS) will announce $12.39 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Merus’ earnings. The lowest sales estimate is $10.40 million and the highest is $13.81 million. Merus posted sales of $9.02 million during the same quarter last year, which would indicate a positive year over year growth rate of 37.4%. The firm is scheduled to report its next quarterly earnings report on Tuesday, March 15th.

According to Zacks, analysts expect that Merus will report full year sales of $46.79 million for the current year, with estimates ranging from $44.80 million to $48.20 million. For the next financial year, analysts anticipate that the company will post sales of $36.14 million, with estimates ranging from $13.33 million to $49.25 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that follow Merus.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Tuesday, November 2nd. The biotechnology company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.14. Merus had a negative net margin of 185.10% and a negative return on equity of 39.37%.

Several equities analysts recently issued reports on the stock. Roth Capital lifted their price target on shares of Merus from $32.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, October 7th. Zacks Investment Research downgraded shares of Merus from a “hold” rating to a “sell” rating in a report on Wednesday, August 11th. Royal Bank of Canada lifted their price target on shares of Merus from $21.00 to $33.00 and gave the company a “sector perform” rating in a report on Wednesday, November 3rd. SVB Leerink lifted their price target on shares of Merus from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Friday, October 8th. Finally, HC Wainwright lifted their price target on shares of Merus from $30.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $38.67.

MRUS stock traded up $1.15 during trading on Thursday, hitting $26.53. 209,977 shares of the stock traded hands, compared to its average volume of 298,686. Merus has a one year low of $15.68 and a one year high of $33.00. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -11.44 and a beta of 0.89. The company has a 50 day simple moving average of $26.81 and a 200 day simple moving average of $23.36.

In other Merus news, major shareholder Bvf Partners L. P/Il sold 985,447 shares of the firm’s stock in a transaction dated Thursday, October 7th. The shares were sold at an average price of $27.53, for a total value of $27,129,355.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.90% of the company’s stock.

Several large investors have recently modified their holdings of the company. BVF Inc. IL grew its position in shares of Merus by 25.5% during the 1st quarter. BVF Inc. IL now owns 7,285,071 shares of the biotechnology company’s stock worth $152,185,000 after buying an additional 1,479,500 shares during the period. Wellington Management Group LLP grew its holdings in Merus by 134.9% during the third quarter. Wellington Management Group LLP now owns 5,009,204 shares of the biotechnology company’s stock valued at $110,201,000 after purchasing an additional 2,876,971 shares during the period. BioImpact Capital LLC grew its holdings in Merus by 34.4% during the third quarter. BioImpact Capital LLC now owns 941,948 shares of the biotechnology company’s stock valued at $20,723,000 after purchasing an additional 241,069 shares during the period. Commodore Capital LP acquired a new position in Merus during the third quarter valued at approximately $15,799,000. Finally, Millennium Management LLC grew its holdings in Merus by 73.8% during the third quarter. Millennium Management LLC now owns 556,523 shares of the biotechnology company’s stock valued at $12,244,000 after purchasing an additional 236,364 shares during the period. Institutional investors own 89.26% of the company’s stock.

Merus Company Profile

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Read More: What is the outlook for the FAANG stocks?

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.